![](https://cdn.benzinga.com/files/imagecache/2048x1536xUP/images/story/2022/movers_image_20964.jpeg)
Gainers
- NeoGenomics (NASDAQ:NEO) stock increased by 29.1% to $9.17 during Tuesday's regular session. Trading volume for this security as of 12:30 EST is 1.1 million, which is 86.3% of its average full-day volume over the last 100 days. The company's market cap stands at $1.1 billion. The company's, Q3 earnings came out today.
- Adaptimmune Therapeutics (NASDAQ:ADAP) stock increased by 26.5% to $2.1. Adaptimmune Therapeutics's stock is trading at a volume of 607.9K shares as of 12:30 EST. This is 150.5% of its average full-day volume over the last 100 days. The company's market cap stands at $343.0 million. The company's, Q3 earnings came out today.
- Hims & Hers Health (NYSE:HIMS) stock increased by 24.45% to $5.75. Hims & Hers Health's stock is trading at a volume of 5.8 million shares as of 12:30 EST. This is 374.7% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $1.1 billion. The company's, Q3 earnings came out yesterday.
- Y-mAbs Therapeutics (NASDAQ:YMAB) shares rose 20.34% to $4.03. The current volume of 879.0K shares is 174.2% of Y-mAbs Therapeutics's average full-day volume over the last 100 days (last updated at 12:30 EST). The company's market cap stands at $176.2 million. The company's, Q3 earnings came out yesterday.
- Ocuphire Pharma (NASDAQ:OCUP) stock increased by 20.19% to $2.5. As of 12:30 EST, Ocuphire Pharma's stock is trading at a volume of 4.7 million, which is 5517.5% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $51.4 million. The company's, Q3 earnings came out 2 days ago.
- Allakos (NASDAQ:ALLK) shares moved upwards by 19.68% to $7.33. As of 12:30 EST, Allakos's stock is trading at a volume of 2.7 million, which is 129.9% of its average full-day volume over the last 100 days. The company's market cap stands at $620.6 million. As per the press release, Q3 earnings came out yesterday.
Losers
- NeuroBo Pharmaceuticals (NASDAQ:NRBO) stock decreased by 44.0% to $1.21 during Tuesday's regular session. As of 12:30 EST, NeuroBo Pharmaceuticals's stock is trading at a volume of 15.4 million, which is 2517.9% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $1.0 million.
- NanoString Technologies (NASDAQ:NSTG) shares decreased by 38.5% to $5.67. NanoString Technologies's stock is trading at a volume of 7.7 million shares as of 12:30 EST. This is 992.2% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $263.6 million. As per the news, the Q3 earnings report came out yesterday.
- Athersys (NASDAQ:ATHX) stock declined by 37.62% to $1.41. The current volume of 1.4 million shares is 101.6% of Athersys's average full-day volume over the last 100 days (last updated at 12:30 EST). The market value of their outstanding shares is at $430.2 million.
- ATI Physical Therapy (NYSE:ATIP) stock fell 24.43% to $0.85. The current volume of 1.2 million shares is 194.4% of ATI Physical Therapy's average full-day volume over the last 100 days (last updated at 12:30 EST). The company's market cap stands at $175.3 million. As per the news, the Q3 earnings report came out yesterday.
- Pennant Gr (NASDAQ:PNTG) stock decreased by 23.33% to $10.39. Trading volume for Pennant Gr's stock is 115.6K as of 12:30 EST. This is 97.8% of its average full-day volume over the last 100 days. The company's market cap stands at $307.0 million. As per the news, the Q3 earnings report came out yesterday.
- Leap Therapeutics (NASDAQ:LPTX) shares declined by 19.88% to $0.61. Trading volume for Leap Therapeutics's stock is 1.8 million as of 12:30 EST. This is 305.7% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $60.7 million. See Also: www.benzinga.com/money/best-healthcare-stocks/
This article was generated by Benzinga's automated content engine and reviewed by an editor.